In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine
Authors:
- Gj PetersGj Peters
- I KraalIKI Kraal
- Hm PinedoHPHm Pinedo
Open Access
- 1 February 1992
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 65 (2) , 229-233
Abstract
Brequinar sodium (DUP-785; Brequinar) is a potent inhibitor of the pyrimidine de novo enzyme dihydroorotate dehydrogenase (DHO-DH), leading to a depletion of pyrimidine nucleotides, which could be reversed by uridine. In in vitro studies we investigated the effect of different physiological concentrations of uridine on the growth-inhibition by Brequinar, the effect of the nucleoside transport inhibitor, dipyridamole, and the combination of Brequinar and 5-fluorouracil (5FU). Uridine at 1 microM slightly reversed the growth inhibition by Brequinar, while the effect of 5-500 microM was greater. However, at Brequinar concentrations greater than 30 microM, uridine could not reverse the growth-inhibitory effects. Addition of dipyridamole could only partially prevent the reversing effects of uridine. The combination of Brequinar and 5FU was more than additive in the absence of uridine in the culture medium, but not in the presence of uridine. The combination of Brequinar and 5FU was tested in vivo in two murine colon tumour models, Colon 26 and Colon 38. Scheduling of both compounds appeared to be very important. In Colon 38 no potentiating effect of Brequinar could be observed. In contrast in Colon 26 a more than additive effect could be observed. Since uridine concentrations are considerably different in these tumours (higher in Colon 38), it was concluded from both the in vitro and in vivo experiments that uridine is an important determinant in combinations of Brequinar and 5FU.Keywords
This publication has 25 references indexed in Scilit:
- Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testingEuropean Journal of Cancer and Clinical Oncology, 1991
- A phase I clinical and pharmacokinetic study of brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly scheduleEuropean Journal of Cancer and Clinical Oncology, 1989
- PHASE-I CLINICAL AND PHARMACOKINETIC TRIAL OF BREQUINAR SODIUM (DUP 785 NSC 368390)1989
- Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancerCancer, 1989
- Cellular Pharmacology of DUP-785, a New Anticancer AgentCancer Communications, 1989
- Distribution of the novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenograftsCancer Chemotherapy and Pharmacology, 1988
- DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effectsBiochemical Pharmacology, 1988
- Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.1988
- Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)Investigational New Drugs, 1987
- MECHANISM OF ACTION OF THE NOVEL ANTICANCER AGENT 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYL-4-QUINOLINECARBOXYLIC ACID SODIUM-SALT (NSC 368390) - INHIBITION OF DENOVO PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS1986